Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA oxidase-like protein (ACOXL) is a peroxisomal enzyme encoded by the ACOXL gene on chromosome 2 in humans. It is predicted to have acyl-CoA oxidase activity, bind fatty acids, and use flavin adenine dinucleotide (FAD) as a cofactor. ACOXL is involved in the peroxisomal beta-oxidation pathway, playing a role in the breakdown of very long-chain fatty acids. It is associated with metabolic pathways and has been linked to diseases such as inflamed seborrheic keratosis and retinitis pigmentosa. Its expression and functional activity suggest potential involvement in lipid metabolism disorders and possibly cancer, but it is not currently known as a direct drug target or as the target of any approved therapies[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA oxidase-like protein (ACOXL).